Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| argenx SE | Empasiprubart (ARGX-117) - (EMVIGORATE) | Chronic inflammatory demyelinating polyneuropathy (CIDP) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod - (UplighTED) | Thyroid eye disease (TED) | Phase 3 | Trial Discontinued | Intravenous | Opthalmic |
| argenx SE | Efgartigimod - (ALPHA) | COVID-19-mediated postural orthostatic tachycardia syndrome (POTS) | Phase 2 | Ongoing | Intravenous | COVID-19 |
| argenx SE | Efgartigimod (ARGX-113) - (ADVANCE) | Immune thrombocytopenia (ITP) | Phase 3 | Data Released | Intravenous | Hematology |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod - (ADAPT-SC) | Primary Immune Thrombocytopenia (ITP) | Phase 3 | Data Released | Subcutaneous | Hematology |
| argenx SE | Empasiprubart (ARGX-117) - (EMPASSION) | Multifocal motor neuropathy (MMN) | Phase 3 | Ongoing | Intravenous | Neurology |
| argenx SE | Efgartigimod - (ALKIVIA) | Myositis subsets (Immune-mediated necrotizing myopathy (IMNM), anti-synthetase syndrome (ASyS), and dermatomyositis (DM)) | Phase 2/3 | Data Released | Intravenous | Immunology |
